Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Concor Tablets (China vs Germany) in Healthy Chinese Participants
NCT05930808Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Feb 2023
- Primary completion
- Jun 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bisoprolol in hypertension (HTN), angina pectoris and chronic heart failure (CHF) (4 arms), sponsored by Merck KGaA. Primary endpoint: Pharmacokinetic Plasma Concentrations of Drug Concor under Fasted and Fed condition. Started Feb 2023; status: completed.
02
Drugs
bisoprolol
03
Conditions
hypertension (HTN)angina pectorischronic heart failure (CHF)
Beyond the preview
Go deeper on NCT05930808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05930808.